United Therapeutics Corporation
UTHR
$515.46
-$12.45-2.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.54% | 6.34% | 11.68% | 14.47% | 16.15% |
| Total Depreciation and Amortization | 14.81% | 14.36% | 18.07% | 24.06% | 31.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 270.08% | 340.15% | 344.96% | -2.15% | 12.64% |
| Change in Net Operating Assets | -78.89% | -508.79% | -2,830.77% | 165.94% | 54.58% |
| Cash from Operations | 22.89% | 10.73% | 17.64% | 36.92% | 24.03% |
| Capital Expenditure | -97.20% | -92.94% | -111.16% | -82.10% | -31.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 432.18% | 552.66% | -104.64% | -101.38% | -157.41% |
| Cash from Investing | 205.95% | 173.96% | -232.14% | -176.72% | -282.99% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 0.00% | -25.00% | -50.00% | -133.33% |
| Issuance of Common Stock | 238.62% | 73.80% | 14.37% | -22.64% | -10.41% |
| Repurchase of Common Stock | -11,975.00% | -15,829.19% | -0.93% | -0.92% | 97.90% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 70.43% | -- | -325.93% | -325.93% | -325.93% |
| Cash from Financing | -414.75% | -805.42% | 8.35% | -3.94% | 64.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.50% | -195.65% | -128.62% | -147.92% | -17.68% |